口服疫苗市场：按疫苗类型、适应症、年龄层和分销管道划分－全球市场预测（2026-2032 年）

预计到 2025 年，口服疫苗市值将达到 41.6 亿美元，到 2026 年将成长至 44.8 亿美元，到 2032 年将达到 73.4 亿美元，复合年增长率为 8.43%。

主要市场统计数据
基准年（2025 年）	41.6亿美元
预计年份（2026年）	44.8亿美元
预测年份（2032年）	73.4亿美元
复合年增长率 (%)	8.43%

本文全面说明了口服疫苗的创新、其公共卫生重要性、科学进展及其在全球范围内的策略和商业性意义。

在不断发展的预防医学领域，口服疫苗正逐渐成为至关重要的治疗方法，在给药、分发和患者接受度方面具有显着优势。过去十年，药物科学、黏膜免疫学和递送技术的进步重新激发了研发人员和公共卫生机构的关注。这些创新旨在降低注射疫苗的接种门槛，提高热稳定性以减轻低温运输负担，并利用黏膜免疫反应更有效地抑制病原体传播。

对科学、监管、分销和患者主导的变革性变化进行分析，这些变化正在重新定义口服疫苗开发和供应的范式。

疫苗领域正经历着一场变革性的转变，其驱动力包括技术突破、相关人员期望的转变以及法规结构的不断改进。在科学层面，mRNA平台、载体设计和抗原稳定性的进步，使得过去无法实现的口服给药方式成为可能。同时，药物科学的进步也为这些进展提供了补充，这些进展能够保护不稳定的分子免受胃肠道降解，并靶向诱导粘膜免疫。因此，研发重点日益集中在维持黏膜免疫、降低剂量策略、简化给药途径。

评估美国在 2025 年实施的关税措施对供应链策略、采购趋势以及製造业在地化相关考量的影响。

美国2025年实施的关税政策调整的累积影响，为疫苗研发、生产和采购机构带来了新的考量。这些贸易措施旨在实现更广泛的产业战略目标，并影响疫苗价值链中的多个环节，包括活性成分、辅料、专用包装材料以及填充和表面处理工程工艺设备的采购。因此，拥有全球分散式供应链的企业需要重新评估筹资策略和成本结构，以降低进口关税增加和港口手续延误带来的风险。

关键的细分见解，整合疫苗平台类型、目标疾病、人口统计需求和分销管道，为确定开发和商业化方案提供有价值的资讯。

要了解市场，需要有系统地掌握产品、临床、人口统计和分销等方面的知识，因为这些方面都会影响研发重点和商业性策略。根据疫苗类型，市场分析涵盖结合疫苗、灭活疫苗、减毒活病毒疫苗、mRNA疫苗和次单位疫苗。考虑到每种疫苗平台在口服给药方面都存在独特的製剂挑战和免疫学特性，这些差异会影响抗原稳定性、给药方案以及保护性辅料和递送介质的选择等决策。

区域洞察：美洲、欧洲、中东和非洲以及亚太地区的差异如何推动监管、製造和分销策略的差异化。

区域趋势对疫苗研发重点、监管合作和分销模式产生显着影响，因此需要在全球市场采取差异化策略。在美洲，官民合作关係、先进的临床试验基础设施和成熟的商业生态系统通常能够明确新给药技术的核准流程，而区域生产能力和采购框架则会影响本地化和策略合作方面的决策。此外，不同国家免疫规划和私部门通路的支付方结构和专案重点也会影响市场渗透率。

本报告从公司层级提供了策略见解，阐述了成熟的製造商、生物技术创新者、CDMO 和相关技术公司如何塑造口服疫苗领域的竞争格局。

口服疫苗领域的竞争动态呈现出多元化的态势，既有成熟的疫苗生产商，也有专注于生物技术创新的企业、合约研发生产机构（CDMO）以及製剂技术供应商。成熟的生产商在规模化生产、法规遵循和大规模分销方面拥有丰富的经验，一旦技术难题得到解决，便能迅速将后期候选产品推向市场。生技公司和大学衍生企业提供颠覆性的平台技术和早期科学研究成果，特别是在黏膜免疫学、口服mRNA递送和保护性赋形剂系统等领域。

为领导者提供切实可行的建议，以透过技术投资、监管合作、供应链多元化和有针对性的商业化来加速口服疫苗的研发。

产业领导者应采取积极主动、多管齐下的策略，将科学潜力转化为易于取得的口服疫苗解决方案，同时管控商业性和地缘政治风险。首先，他们必须投资于平台能力建设，以解决製剂稳定性和黏膜免疫抗原性，并透过与製剂专家和学术机构合作，加速临床前知识的获取，降低临床应用风险。同时，他们应儘早整合监管策略，与监管机构合作，明确新型给药途径的证据要求，从而缩短研发週期，并降低不不确定性。

透明的调查方法结合了与专家的直接访谈、文献整合、案例研究分析和资料检验，确保了研究结果的平衡性和可操作性。

本研究采用严谨的调查方法，结合一手和二手调查资料，透过综合分析得出可靠且令人信服的结论。一手调查包括对疫苗研发、临床研究、监管事务、生产营运和公共卫生采购等领域的专家进行结构化访谈和咨询，从而深入了解技术挑战和策略重点。此外，本研究也分析了相关的同侪审查文献、临床试验註册资讯、监管指南和技术白皮书，使研究结果与当代科学和政策紧密结合。

总结部分重点阐述了口服疫苗的潜力、仍然存在的科学和操作方面的挑战，以及产业和政策制定者需要采取协调行动。

总之，口服疫苗为扩大疾病预防手段提供了策略机会，其优势在于无需注射、可能增强黏膜免疫力，且分发效率高，符合现代公共卫生优先事项。科学技术的进步正逐步消除抗原稳定性和胃肠道递送方面的传统障碍，监管流程也在积极参与下得到简化。然而，挑战依然存在，包括需要获得涵盖所有年龄层的可靠安全性和有效性数据、可扩展的生产流程以及能够适应基础设施容量波动的灵活供应模式。

目录

第一章 引言

第二章 分析方法

• 分析设计
• 分析框架
• 市场规模预测
• 数据三角测量
• 分析结果
• 分析的前提条件
• 分析的局限性

第三章执行摘要

• 首席体验长的观点
• 市场规模和成长趋势
• 市占率分析（2025 年）
• FPNV定位矩阵（2025）
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 市场进入（GTM）策略

第五章 市场洞察

• 消费者分析与最终用户观点
• 消费者体验基准测试
• 机会映射
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 成本效益分析（ROI）和成本效益分析（CBA）

第六章：美国关税的累积影响（2025 年）

第七章：人工智慧（AI）的累积影响（2025 年）

第八章 口服疫苗市场：依疫苗类型划分

• 结合疫苗
• 灭活疫苗
• 减毒活病毒疫苗
• 药效疫苗
• 次单位疫苗

第九章 口服疫苗市场：依适应症划分

• 流感
• 诺罗病毒
• 脊髓灰质炎
• 轮状病毒

第十章 口服疫苗市场：依年龄组别划分

• 成人
• 老年人
• 儿童

第十一章 口服疫苗市场：依通路划分

• 医院和诊所
• 网路药房
• 药局

第十二章 口服疫苗市场：依地区划分

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 口服疫苗市场：依组别划分

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 口服疫苗市场：依国家划分

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章：美国口服疫苗市场

第十六章：中国口服疫苗市场

第十七章 竞争格局

• 市场集中度分析（2025 年）
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析（2025 年）
• 产品系列分析（2025 年）
• 基准分析（2025 年）
• AstraZeneca plc
• Bharat Biotech International Limited
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Moderna, Inc
• Panacea Biotec Ltd.
• PT Bio Farma（Persero）
• Sanofi SA
• Sinovac Biotech Ltd
• Valneva SE

The Oral Vaccine Market was valued at USD 4.16 billion in 2025 and is projected to grow to USD 4.48 billion in 2026, with a CAGR of 8.43%, reaching USD 7.34 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 4.16 billion
Estimated Year [2026]	USD 4.48 billion
Forecast Year [2032]	USD 7.34 billion
CAGR (%)	8.43%

Comprehensive introduction framing oral vaccine innovation, public health relevance, scientific advancements, and strategic commercial implications worldwide

Oral vaccines are emerging as a pivotal modality in the evolving landscape of preventive medicine, offering distinct advantages across administration, distribution, and patient acceptance. Over the past decade, advances in formulation science, mucosal immunology, and delivery technologies have converged to renew interest from developers and public health authorities alike. These innovations seek to reduce barriers associated with needle-based vaccination, improve thermostability to ease cold chain burdens, and exploit mucosal immune responses to interrupt pathogen transmission more effectively.

As stakeholders reassess immunization strategies, the oral vaccine proposition extends beyond convenience to encompass supply chain efficiencies and potential cost reductions in administration. In clinical contexts, oral delivery can facilitate mass immunization campaigns and targeted programs where trained personnel are scarce, thereby supporting equity goals. Concurrently, the scientific community continues to refine antigen presentation, adjuvant selection, and vector design to enhance immunogenicity across demographic groups, including pediatric and geriatric populations.

This introduction sets the stage for a nuanced examination of the drivers, barriers, and strategic considerations shaping oral vaccine development and commercialization. It emphasizes the interplay between scientific innovation, regulatory pathways, and distribution models, which collectively determine the pace at which oral vaccines transition from promising candidates to routine components of global immunization programs. The aim is to provide a balanced baseline that informs subsequent sections focused on landscape shifts, trade implications, segmentation dynamics, regional variations, corporate strategies, and pragmatic recommendations for leaders across the ecosystem.

Analysis of the transformative scientific, regulatory, distributional, and patient-driven shifts redefining the oral vaccine development and delivery paradigm

The vaccine landscape is undergoing transformative shifts driven by technological breakthroughs, altered stakeholder expectations, and evolving regulatory frameworks. At the scientific level, progress in mRNA platforms, vector design, and antigen stabilization is enabling new approaches to oral delivery that were previously impractical. These advances are complemented by improvements in formulation science that protect labile molecules from gastrointestinal degradation and target mucosal immune induction. As a result, development priorities are increasingly centered on durable mucosal immunity, dose-sparing strategies, and simplified administration.

Concurrently, public health priorities have shifted toward resilient immunization systems that can respond to both endemic pathogens and emergent threats. This focus on resilience favors modalities that simplify logistics, such as needle-free administration and formulations with relaxed cold chain requirements. Regulatory agencies are evolving their guidance to accommodate novel delivery technologies, creating clearer pathways for bridging trials and real-world evidence generation. Private sector investors and strategic partners are responding by rebalancing portfolios to include early-stage oral candidates and platform technologies that promise scalability.

Moreover, end-user expectations and healthcare delivery models are reshaping commercial approaches. Patients and caregivers increasingly prioritize convenience and minimal invasiveness, which supports the adoption of oral vaccines in community and outpatient settings. Digital health tools and telemedicine are also influencing vaccine delivery by enabling scheduling, adherence tracking, and remote monitoring. Taken together, these shifts create a dynamic playing field where scientific feasibility, regulatory clarity, patient-centered design, and distribution innovation intersect to accelerate the translation of oral vaccine concepts into practice.

Evaluation of how United States tariff measures enacted in 2025 have reshaped supply chain strategies, procurement dynamics, and manufacturing localization considerations

The cumulative impact of tariff policy changes enacted in the United States in 2025 has introduced a new set of considerations for vaccine developers, manufacturers, and procurement entities. These trade measures, while aimed at broader industrial strategy objectives, affect multiple nodes of the vaccine value chain, including the sourcing of active pharmaceutical ingredients, excipients, specialized packaging materials, and equipment used in fill-and-finish operations. As a consequence, organizations with globally distributed supply chains must reassess sourcing strategies and cost structures to mitigate exposure to increased import duties and procedural delays at ports.

In practical terms, the policy shift has accelerated conversations around supply chain localization, dual sourcing, and strategic stockpiling of critical inputs. Manufacturers are investigating nearshoring options and expanding relationships with domestic contract development and manufacturing organizations to reduce tariff-related vulnerabilities. These changes also influence contract negotiation dynamics with suppliers, where greater emphasis is placed on price transparency, freight optimization, and shared risk agreements. Procurement teams are increasingly modeling the downstream operational implications of tariffs, such as altered lead times and inventory turnover, to preserve continuity of supply for clinical programs and immunization campaigns.

For public purchasers and financing institutions, tariffs introduce complexities in budgeting and procurement timelines, prompting renewed interest in long-term supply agreements and incentivized manufacturing investments within tariff-favored jurisdictions. Importantly, the policy environment has encouraged cross-sector collaboration to balance national strategic goals with global health imperatives, including multilateral dialogues to ensure that tariff measures do not impede access to life-saving vaccines. Looking ahead, the industry is adapting through a combination of operational resilience measures, strategic partnerships, and targeted capital investments aimed at maintaining programmatic continuity while aligning with evolving trade realities.

Key segmentation insights integrating vaccine platform types, disease targets, demographic needs, and distribution channels to inform development and commercialization choices

Understanding the market requires a structured view across product, clinical, demographic, and distribution dimensions, each of which shapes development priorities and commercial approaches. Based on Vaccine Type, market analyses consider Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines, and Subunit Vaccines, recognizing that each platform presents distinct formulation challenges and immunological profiles for oral delivery. These differences influence decisions around antigen stability, dosing schedules, and the selection of protective excipients or delivery vehicles.

Based on Disease Indication, attention is given to key targets such as Influenza, Norovirus, Poliovirus, and Rotavirus, where oral delivery can offer strategic benefits in terms of mucosal immunity and population-level transmission interruption. The landscape for each indication varies by historical precedent, clinical endpoints, and regulatory expectations, affecting the pace and complexity of development programs. Based on Age Group, distinctions among Adult, Geriatric, and Pediatric populations underscore the need to tailor formulations, dosing strategies, and safety monitoring to physiological and immunological differences across the lifespan.

Finally, Based on Distribution Channel, routes to market such as Hospitals & Clinics, Online Pharmacy, and Pharmacies define the operational requirements for packaging, labeling, and cold chain management, as well as the patient engagement and adherence supports needed. Integrating these segmentation lenses reveals nuanced commercial pathways: certain vaccine types may align more naturally with mass campaign models and hospital-based distribution, while others could be optimized for retail pharmacy or direct-to-consumer channels. This layered segmentation informs prioritization for developers and commercial teams as they balance scientific feasibility with route-to-market realities.

Regional insights highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific variations drive differentiated regulatory, manufacturing, and distribution strategies

Regional dynamics exert a profound influence on vaccine development priorities, regulatory interactions, and distribution models, necessitating a differentiated approach across global markets. In the Americas, public-private partnerships, advanced clinical trial infrastructure, and a mature commercial ecosystem often accelerate pathway clarity for novel delivery technologies, while regional manufacturing capacity and procurement frameworks shape decisions around localization and strategic alliances. Market adoption is also influenced by payer structures and programmatic priorities that vary between national immunization programs and private sector channels.

Europe, Middle East & Africa present a spectrum of regulatory environments and healthcare delivery models that require adaptive strategies. In some European markets, harmonized regulatory processes and strong pharmacovigilance systems facilitate lifecycle planning, whereas in certain Middle Eastern and African contexts, emphasis is placed on affordability, cold chain logistics, and integration with existing immunization schedules. Collaborative initiatives and donor-supported procurement remain critical levers to expand access in regions where infrastructure limitations challenge distribution of temperature-sensitive products.

Asia-Pacific demonstrates substantial heterogeneity, with advanced manufacturing hubs, strong biopharmaceutical innovation ecosystems, and high-capacity public health programs in some markets, juxtaposed with emerging markets where infrastructure investments are ongoing. Regional supply chains, translational science collaborations, and differences in disease burden inform clinical trial design and deployment strategies. These regional insights underscore the need for tailored regulatory engagement, manufacturing footprint decisions, and distribution partnerships that align with local priorities and operational realities.

Strategic company-level insights on how incumbent manufacturers, biotech innovators, CDMOs, and allied technology firms are shaping competitive trajectories in oral vaccines

Competitive dynamics in the oral vaccine domain reflect a mix of established vaccine manufacturers, specialized biotech innovators, contract development and manufacturing organizations, and formulation technology providers. Established manufacturers bring experience in scale-up, regulatory navigation, and large-scale distribution, positioning them to accelerate late-stage candidates toward broad deployment when technical challenges are resolved. Biotechnology firms and academic spinouts contribute disruptive platform technologies and early-stage science, particularly in areas such as mucosal immunology, oral mRNA delivery, and protective excipient systems.

Contract development and manufacturing organizations play an increasingly central role by offering technical expertise in specialized formulation, encapsulation, and fill-and-finish processes that are critical for oral product viability. Collaboration between platform owners and CDMOs often determines speed to clinic and commercial scalability. Additionally, companies focused on cold chain optimization, packaging innovation, and digital supply chain solutions are creating complementary capabilities that reduce logistical friction and improve adherence monitoring.

Strategic partnerships, licensing arrangements, and public-private collaborations are recurring motifs, enabling risk-sharing and leveraging of complementary strengths. Intellectual property strategies and platform modularity influence competitive differentiation, as does the ability to generate robust safety and immunogenicity data across diverse populations. For stakeholders evaluating partnership prospects or competitive positioning, the emphasis is on technological fit, regulatory experience, manufacturing scalability, and the capacity to address end-to-end delivery challenges.

Actionable recommendations for leaders to accelerate oral vaccine development through technology investment, regulatory engagement, supply chain diversification, and targeted commercialization

Industry leaders should adopt a proactive, multi-dimensional strategy to translate scientific promise into accessible oral vaccine solutions while managing commercial and geopolitical risks. First, invest in platform capabilities that address formulation stability and mucosal immunogenicity, including partnerships with formulation specialists and academic centers to accelerate preclinical learnings and de-risk clinical translation. Simultaneously, integrate regulatory strategy early by engaging with agencies to clarify evidence requirements for novel delivery routes, thereby shortening development timelines and reducing uncertainty.

Operationally, diversify supply chains to mitigate exposure to trade policy shifts and material bottlenecks. Establish strategic relationships with regional manufacturing partners and CDMOs to enable flexible production footprints and responsive scaling. On the commercial side, develop distribution models that align with target demographics and channels-hospitals and clinics for high-acuity programs, pharmacies for routine adult immunizations, and online pharmacy solutions to enhance access and adherence in digitally enabled markets. Complement these efforts with digital tools for patient education, scheduling, and post-market surveillance.

Finally, prioritize stakeholder engagement to build confidence among payers, public health authorities, and community leaders. Invest in robust real-world evidence generation and pharmacovigilance frameworks to demonstrate safety and effectiveness across age groups. By balancing scientific rigor, regulatory foresight, operational resilience, and targeted commercial execution, industry leaders can position their portfolios to capture the full potential of oral vaccine innovations.

Transparent research methodology combining expert primary interviews, literature synthesis, case study analysis, and data triangulation to ensure balanced and actionable insights

This research synthesis is underpinned by a rigorous methodology that integrates primary and secondary inputs to ensure robust, defensible conclusions. Primary research included structured interviews and consultations with subject-matter experts from vaccine development, clinical research, regulatory affairs, manufacturing operations, and public health procurement, providing practical insights into technical challenges and strategic priorities. These engagements were complemented by analysis of relevant peer-reviewed literature, clinical trial registries, regulatory guidance, and technical white papers to ground findings in contemporary science and policy.

Data synthesis employed cross-validation techniques to reconcile differing perspectives and triangulate conclusions, placing particular emphasis on reproducibility of clinical and operational observations. The study also reviewed anonymized case examples of process development and distribution implementations to extract transferable lessons and risk mitigation strategies. Quality assurance steps included expert review cycles, methodological transparency for key assumptions, and iterative refinement based on stakeholder feedback to enhance applicability across diverse organizational contexts.

Where appropriate, the methodology identified areas of uncertainty and recommended targeted research to address gaps, such as comparative immunogenicity studies across delivery platforms and operational pilots for alternative distribution channels. The approach balances depth and pragmatism to deliver insights that are both scientifically grounded and operationally actionable for decision-makers.

Conclusive synthesis emphasizing the promise of oral vaccines, residual scientific and operational challenges, and the need for coordinated industry and policy action

In conclusion, oral vaccines represent a strategic opportunity to broaden the toolkit for disease prevention by offering needle-free administration, potential improvements in mucosal immunity, and distribution efficiencies that align with contemporary public health priorities. Scientific and technological advances are progressively addressing historical barriers related to antigen stability and gastrointestinal delivery, while regulatory pathways are becoming more navigable through proactive engagement. Yet, challenges remain, including the need for robust safety and efficacy data across age cohorts, scalable manufacturing processes, and adaptive distribution models that handle variable infrastructure capacities.

External factors such as trade policy shifts and regional heterogeneity in healthcare delivery further complicate the pathway to broad adoption, underscoring the importance of resilient supply chain design and region-specific strategies. Industry players that combine platform innovation, strategic partnerships, and operational agility will be best positioned to translate oral vaccine potential into sustainable public health impact. Ultimately, success will require coordinated effort among developers, regulators, manufacturers, payers, and public health stakeholders to ensure that promising technologies are translated into accessible, safe, and effective interventions that meet the needs of diverse populations.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Vaccine Market, by Vaccine Type

• 8.1. Conjugate Vaccines
• 8.2. Inactivated Vaccines
• 8.3. Live Attenuated Vaccines
• 8.4. Mrna Vaccines
• 8.5. Subunit Vaccines

9. Oral Vaccine Market, by Disease Indication

• 9.1. Influenza
• 9.2. Norovirus
• 9.3. Poliovirus
• 9.4. Rotavirus

10. Oral Vaccine Market, by Age Group

• 10.1. Adult
• 10.2. Geriatric
• 10.3. Pediatric

11. Oral Vaccine Market, by Distribution Channel

• 11.1. Hospitals & Clinics
• 11.2. Online Pharmacy
• 11.3. Pharmacies

12. Oral Vaccine Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Oral Vaccine Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Oral Vaccine Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Oral Vaccine Market

16. China Oral Vaccine Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. AstraZeneca plc
• 17.6. Bharat Biotech International Limited
• 17.7. Emergent BioSolutions Inc.
• 17.8. GlaxoSmithKline plc
• 17.9. Merck & Co., Inc.
• 17.10. Moderna, Inc
• 17.11. Panacea Biotec Ltd.
• 17.12. PT Bio Farma (Persero)
• 17.13. Sanofi S.A.
• 17.14. Sinovac Biotech Ltd
• 17.15. Valneva SE

LIST OF FIGURES

• FIGURE 1. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ORAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL ORAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 52. AMERICAS ORAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 53. AMERICAS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 54. AMERICAS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 55. AMERICAS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 56. AMERICAS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 57. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 58. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 59. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 60. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 61. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 62. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 64. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 65. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 66. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 67. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 68. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 69. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 70. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 71. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 72. EUROPE ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 73. EUROPE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 74. EUROPE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 75. EUROPE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 76. EUROPE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 77. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 78. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 79. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 80. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 81. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 82. AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 83. AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 84. AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 85. AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 86. AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 87. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 88. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 89. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 90. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 91. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 93. ASEAN ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 94. ASEAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 95. ASEAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 96. ASEAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 97. ASEAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 98. GCC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 99. GCC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 100. GCC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 101. GCC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 102. GCC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 103. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 104. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 105. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 106. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 107. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 108. BRICS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 109. BRICS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 110. BRICS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 111. BRICS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 112. BRICS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 113. G7 ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 114. G7 ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 115. G7 ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 116. G7 ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 117. G7 ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 118. NATO ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 119. NATO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 120. NATO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 121. NATO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 122. NATO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 123. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 124. UNITED STATES ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 125. UNITED STATES ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 126. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 127. UNITED STATES ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 128. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
• TABLE 129. CHINA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 130. CHINA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
• TABLE 131. CHINA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
• TABLE 132. CHINA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 133. CHINA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)